[1]《医学免疫学》人民卫生出版社,第九版
[2]Pan HX, Wu QH, Zeng G, et al. Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. medrxiv. 2021.07.23.21261026v1.
[3]Ma C , Xu S , Yao Y , et al. Mild Breakthrough Infection in a Healthcare Professional Working in the Isolation Area of a Hospital Designated for Treating COVID-19 Patients — Shaanxi Province, China, March, 2021[J]. China CDC Weekly, 2021, 3(19):397-400.